Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2026 Earnings Call Transcript April 29, 2026Teva Pharmaceutical Industries Limited beats earnings expectations.
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bourgeon Capital John Zaro | 286,257 | $8,622,061 | -54% | 1.49% |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 200,000 | $7,014,000 | -53% | 1.59% |
| 3. | Factorial Partners Mark Kleiman | 232,000 | $6,987,840 | -20% | 5.07% |
| 4. | 148,500 | $4,472,820 | -59% | 0.02% | |
| 5. | ARK Investment Management Catherine D. Wood | 68,279 | $2,056,563 | -36% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.86 | 1,113 | $20,988.06 | 13,027 | 2025-09-05 | Filing | |
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.00 | 10,679 | $384,444.00 | 20,016 | 2026-05-06 | Filing | |
| $35.40 | 30,000 | $1,062,000.00 | 55,755 | 2026-05-05 | Filing | |
| $34.99 | 144,180 | $5,045,117.72 | 80,760 | 2026-05-01 | Filing | |
| $35.31 | 21,258 | $750,619.98 | 63,647 | 2026-04-30 | Filing | |
| $30.14 | 62,102 | $1,871,816.38 | 224,940 | 2026-03-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 42,777,414 | $1,288,455,710 | 12.21% | |
| 2. | 40,820,600 | $1,157,264,010 | 2.64% | |
| 3. | 4,227,900 | $127,344,348 | 0.07% | |
| 4. | 3,885,683 | $117,036,772 | 3.92% | |
| 5. | 3,872,811 | $116,649,066 | 0.03% |
News See All
Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?
Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra.
Billionaire Druckenmiller and Jim Cramer Like These Stocks
Stanley Druckenmiller and Jim Cramer are two of the closely followed voices in financial markets. Though sometimes their stock preferences differ, they always draw widespread investor attention.
10 Stocks Notching Impressive Double-Digit Gains
Meanwhile, Wall Street’s three main indices were left in the dust, with the Nasdaq the only gainer, albeit by a mere 0.04 percent.
15 Under-the-Radar Picks from David Einhorn That Are Quietly Dominating 2026
David Einhorn, the founder and president of Greenlight Capital, is widely regarded as one of the most intellectually rigorous and disciplined value investors of his generation.
David Einhorn Stock Portfolio: Top 10 Stock Picks
David Einhorn of Greenlight Capital manages a 13F portfolio that was worth more than $2.8 billion at the end of the fourth quarter of 2025.
8 Cheap Large Cap Stocks to Buy Now
Cheap large-cap stocks are getting more attention as investors are looking past the market’s most crowded winners and are now putting more weight on the current entry points.
Billionaire Stan Druckenmiller's 10 Small and Mid-Cap Stock Picks with Huge Upside Potential
Stanley Druckenmiller, the founder of New York-based Duquesne Family Office, oversees a 13F portfolio at his hedge fund that was worth close to $4.5 billion at the end of the fourth quarter of 2025.
Factors Supporting Teva Pharmaceutical's (TEVA) Long-Term Profitability
TCW funds, an investment management company, released its “TCW Relative Value Mid Cap Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
13 Cheapest Strong Buy Stocks to Buy Right Now
Buying stocks with a low forward Price-to-Earnings (P/E) ratio is a classic value-investing approach centered on identifying companies that may be undervalued relative to their expected future earnings...
Hedge Fund Resource Center